Purchase this article with an account.
Rana Mady, Frank Spellman, Marcus Colyer; Intravitreal Bevacizumab for Retinal Arterial Macroaneurysm: A Case Series. Invest. Ophthalmol. Vis. Sci. 2014;55(13):673.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To further elucidate the role of anti-vascular endothelial growth factor (anti-VEGF) therapy in the treatment of macular complications following retinal arterial macroaneurysm and to potentially broaden its therapeutic role in this retinal disorder.
Retrospective case series of ten patients that were treated with intravitreal bevacizumab either alone or in conjunction with focal laser or surgery for macular complications secondary to retinal arterial macroaneurysm between the years of 2010 to 2013 at the Retina Group of Washington. Central macular thickness and visual acuity data were collected at presentation and after intravitreal injection at 1 month, 3 months and 6 months of follow-up. This research was approved by the Institutional Review Board of the MedStar Health Research Institute.
A total of 10 patients were included in the study. Four patients presented with hemorrhagic complications, 3 with lipid exudates and 3 with a combination of both. Follow-up time ranged from 3 - 14 months (mean 7.6 months). Average best-corrected visual acuity (BCVA) in logMAR was 1.34 (range 0.3 - 1.6) at presentation and 0.7 (range 0 - 1.6) at final follow-up. Eight out of 10 patients had improved visual acuity at final follow-up compared to initial presentation. Clinically, macular edema completely resolved in all cases. Central macular thickness (CMT) data is available for patients #7-10. Average CMT at presentation was 443.5μm (range 331-687) and at final follow-up was 202μm (range 168-240).
Overall, macular edema resolved in all cases. Visual acuity improved in 8 out of the 10 cases.
This PDF is available to Subscribers Only